[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse CD63

Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Lysosome membrane Multi-pass membrane protein Late endosome membrane Multi-pass membrane protein Endosome, multivesicular body Melanosome Secreted, exosome Cell surface Note=Also found in Weibel-Palade bodies of endothelial cells (PubMed:10793155). Located in platelet dense granules (PubMed:7682577). Detected in a subset of pre-melanosomes. Detected on intralumenal vesicles (ILVs) within multivesicular bodies (PubMed:21962903).
Domain PF00335 Tetraspanin family
Function

Functions as cell surface receptor for TIMP1 and plays a role in the activation of cellular signaling cascades. Plays a role in the activation of ITGB1 and integrin signaling, leading to the activation of AKT, FAK/PTK2 and MAP kinases. Promotes cell survival, reorganization of the actin cytoskeleton, cell adhesion, spreading and migration, via its role in the activation of AKT and FAK/PTK2. Plays a role in VEGFA signaling via its role in regulating the internalization of KDR/VEGFR2. Plays a role in intracellular vesicular transport processes, and is required for normal trafficking of the PMEL luminal domain that is essential for the development and maturation of melanocytes. Plays a role in the adhesion of leukocytes onto endothelial cells via its role in the regulation of SELP trafficking. May play a role in mast cell degranulation in response to Ms4a2/FceRI stimulation, but not in mast cell degranulation in response to other stimuli.

> Gene Ontology
 
Biological Process GO:0002090 regulation of receptor internalization
GO:0002092 positive regulation of receptor internalization
GO:0002576 platelet degranulation
GO:0006887 exocytosis
GO:0006898 receptor-mediated endocytosis
GO:0007034 vacuolar transport
GO:0007160 cell-matrix adhesion
GO:0007229 integrin-mediated signaling pathway
GO:0010959 regulation of metal ion transport
GO:0015672 monovalent inorganic cation transport
GO:0016197 endosomal transport
GO:0021700 developmental maturation
GO:0030100 regulation of endocytosis
GO:0031589 cell-substrate adhesion
GO:0031623 receptor internalization
GO:0033059 cellular pigmentation
GO:0035646 endosome to melanosome transport
GO:0035826 rubidium ion transport
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0038084 vascular endothelial growth factor signaling pathway
GO:0043112 receptor metabolic process
GO:0043473 pigmentation
GO:0043476 pigment accumulation
GO:0043482 cellular pigment accumulation
GO:0043485 endosome to pigment granule transport
GO:0045055 regulated exocytosis
GO:0045807 positive regulation of endocytosis
GO:0048066 developmental pigmentation
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048260 positive regulation of receptor-mediated endocytosis
GO:0048757 pigment granule maturation
GO:0050931 pigment cell differentiation
GO:0060627 regulation of vesicle-mediated transport
GO:0090287 regulation of cellular response to growth factor stimulus
GO:1900746 regulation of vascular endothelial growth factor signaling pathway
GO:1902547 regulation of cellular response to vascular endothelial growth factor stimulus
GO:2000680 regulation of rubidium ion transport
GO:2001044 regulation of integrin-mediated signaling pathway
GO:2001046 positive regulation of integrin-mediated signaling pathway
Molecular Function -
Cellular Component GO:0005765 lysosomal membrane
GO:0005770 late endosome
GO:0005771 multivesicular body
GO:0005775 vacuolar lumen
GO:0010008 endosome membrane
GO:0030141 secretory granule
GO:0030659 cytoplasmic vesicle membrane
GO:0030667 secretory granule membrane
GO:0031088 platelet dense granule membrane
GO:0031902 late endosome membrane
GO:0031904 endosome lumen
GO:0032585 multivesicular body membrane
GO:0042470 melanosome
GO:0042827 platelet dense granule
GO:0044440 endosomal part
GO:0048770 pigment granule
GO:0097487 multivesicular body, internal vesicle
GO:0098852 lytic vacuole membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04142 Lysosome
Reactome R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD63 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD63 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28507029Cervical CarcinomaPromote immunity (T cell function)CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8+T Cell Responses. CD63 delivery into EVs led to better CD8+T cell responses than calnexin delivery into the endoplasmic reticulum.
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD63 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD63 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0620.847
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0870.987
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1690.964
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1030.807
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0090.997
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2230.947
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2640.676
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3880.892
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.130.967
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.030.993
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0980.985
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0410.562
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD63 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD63. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD63. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD63.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD63. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD63 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD63 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD63
NameCD63 molecule
Aliases ME491; TSPAN30; MLA1; CD63 antigen (melanoma 1 antigen); OMA81H; granulophysin; melanoma-associated antigen ......
Chromosomal Location12q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD63 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.